Introduction
(5). Further, expectorate is difficult to collect from infants and so samples are usually collected 48 by oropharyngeal swab. This creates problems interpreting the presence of organisms in 49 samples, because presence in the upper respiratory tract is not always indicative of lower 50 airway infection (6, 7). 51 52 Moreover, the association of S. aureus with progressive lung disease -as measured by 53 worsening lung function and the development of subsequent infection by the chronic CF 54
pathogen Pseudomonas aeruginosa -is unclear (8). S. aureus is able to rapidly adapt to and 55 persist in the CF lung environment (9), and worsening lung condition has been associated with 56 the formation of S. aureus small colony variants (SCVs) (10). SCVs are known to remain in the 57 lung longer than wild type (WT) bacterial cells (11) and demonstrate increased antimicrobial 58 resistance (12). In studies of bronchoalveolar lavage (BAL) fluid in children aged 0-7 years, 59
both Gangell et al. and Sagel et al. (13, 14) found that positive S. aureus culture was linked to 60 a higher degree of airway inflammation as measured by increased neutrophil count and IL-8.
The lack of understanding regarding the role of S. aureus in the development of lung disease 69 in CF has led to debate over the use of anti-staphylococcal prophylaxis early in life. Studies by 70
Ratjen et al. and Stutman et al. (18, 19) linked the use of broad-spectrum antibiotics to an 71 increase in P. aeruginosa isolation. However, a recent Cochrane review (20) showed no effect 72 of anti-staphylococcal prophylaxis on P. aeruginosa colonisation at 3-4 years. There was a 73 suggested trend towards higher rates of P. aeruginosa at 4-6 years but as the studies reviewed 74 did not last more than six years, conclusions about the long-term effects of prophylaxis could 75 not be drawn. A pragmatic randomized controlled trial is currently in progress 76 (http://www.cfstart.org.uk). 77
78
In addition to the lack of clarity over the clinical consequences of S. aureus colonisation, there 79 is also a gap in our mechanistic understanding of the microbiology of S. aureus in CF. The 80 interaction of S. aureus with the pulmonary airway in CF, and its subsequent role in 81 pathogenesis, is not clearly documented. CF epithelial cells have been shown to have an 82 increased abundance of aGM1, a receptor that binds S. aureus and P. aeruginosa, compared 83 with wild-type epithelia (21). In addition, an in vitro study by Schwab et al. demonstrated that 84 bacterial adherence to a bronchial epithelial cell line was significantly greater for CF S. aureus 85 isolates than non-CF (22). Yet, the only study we could find which included direct evidence of 86 S. aureus infection in human biopsy specimens, demonstrated that S. aureus did not adhere 87 to the airway epithelium but was found aggregating within the mucus (23). Furthermore, it 88
suggested that binding to mucin in CF airways may be more efficient than to mucins produced 89 in other infections. This is supported by Yildirim et al. (24) , who showed S. aureus isolated in 90 only 10% of samples in a study of chronic sinusitis. It is obvious that better understanding of 91 just how S. aureus colonizes the pulmonary airway in CF is required, as well as more 92 unambiguous data on the underlying mechanisms of pathogenesis and virulence, and the 93 influence S. aureus has on subsequent infection by other microorganisms. The development 94 of a clinically relevant, high throughput model of infection to dissect the microbiology of S. 95 aureus in CF is therefore needed. 96
97
Mice are the most commonly used animal model of pulmonary infection in CF. Mouse models 98 have been used to identify virulence-related genes in pathogens and to test novel therapeutic 99 agents aimed at reducing inflammation or infection (25). However, mouse models present a 100 number of challenges. In particular, mice do not develop spontaneous P. aeruginosa 101 endobronchial infection, suppurative lung disease and mucus plugging of the airways that are 102 fundamental characteristics of human CF progression (26). S. aureus does not appear to 103 readily colonize the airways of mice or produce an inflammatory response, even when clinical 104 strains are used, in the presence of mucus (27). Furthermore, despite one murine study 105 demonstrating that S. aureus did increase the likelihood of subsequent chronic P. aeruginosa 106 infection, it also promoted severe abscess-like lesions in the lung (28). When lung abscess 107 does occur in humans, S. aureus is the most commonly isolated organism (29). However, lung 108 abscess is rare in children (30) and even more so in CF patients: since the advent of neonatalscreening and survival past infancy, abscesses are almost never observed in the CF population 110 (31-33). 111 112
We have previously described an ex vivo pig lung model of P. aeruginosa airway infection in 113 CF using alveolar and bronchiolar tissue sections and an artificial sputum media (ASM) 114 designed to mimic CF mucus (34, 35). Here, we report that the model supports the growth of 115 S. aureus as biofilm-like aggregates on the surface of bronchioles and in the surrounding 116 artificial sputum, without the formation of abscesses or other significant ultrastructural 117 changes to tissue. We show that S. aureus can be maintained in the model over 7 days (a 118 notable improvement over the short-term nature of live murine models) and appears to grow 119 in a similar way to that observed in human disease, including the presence of SCVs and a 120 potential preference for aggregation in the surrounding mucus rather than tissue invasion. 121
The work presented here is of importance not only for studying the colonisation of CF airway 122 with S. aureus and the progression of S. aureus infection, but also lays the groundwork for 123 future studies using this model to investigate interaction between S. aureus and other 124 Artificial sputum medium (ASM) was prepared according to Palmer et al. (36) with the 140 modification that we removed glucose and supplemented with 20 µg ml −1 ampicillin. Our 141 previous work suggested that glucose facilitated the growth of endogenous bacteria present 142 in the lungs and that ampicillin helped to limit the growth of any resident bacteria in the lung 143 that remained after sterilisation (35). We selected a concentration of ampicillin that provided 144 the best possible coverage against endogenous populations but was sub-inhibitory for the S. were weak fermenters or small in size was initially confirmed using hydrogen peroxide to test 201 for the production of catalase and a staphylase assay (Oxoid). If SCVs were suspected, colonieswere recovered by aerobic incubation overnight on Columbia Blood Agar and morphology 203 was compared to the originally inoculated parent strain. PCR of large and small colonies from 204 MSA plates was used to verify taxon identity in two ways: first, we ran colony PCR using 205
Staphylococcus-specific primers (38) and once genus was confirmed we amplified the 16S-206 23S rRNA intergenic spacer region and sequencing was used to confirm that SCVs were S. 207 aureus (primers 5'-TGCCAAGGCATCCACCG-3' and 5'-GGCTGGATCACCTCCTT-3'). 
268
Growth within the model depends on strain and lung but trends in growth are consistent 270 overtime. To further test the reproducibility of the results for the model, and the ability to 271 observe differences between strains within the model, triplicate samples of USA300 and two 272 clinical strains were inoculated into three further lungs taken from different pigs (Fig 2) . 273
Clinical isolate FQ151 was compared to FQ184, a strain demonstrating similar characteristics 274 to FQ151 but isolated during an acute disease exacerbation (Table 1 ). Figure 2 shows that, 275 when repeated, USA300 was again able to establish in the lung and mean bacterial load 276 recovered at 48 h was 6.8 x 10 6 CFU. Mean yields for clinical strains at 48 h were 3.8 x 10 6 and 277 5.5 x10 5 CFU for FQ184 and FQ151, respectively. By 7 days no colonies were recovered from 278 tissue taken from one of the three lungs for either clinical strain, and counts for clinical strains 279 in a second lung were below or close to the lower limit of detection. Average CFU counts at 280 day 7 were 4.2 x 10 3 for USA300, 7.9 x 10 3 for FQ184 and 8. 
339

S. aureus aggregates in artificial sputum surrounding lung tissue. Initial experiments (Figs 1, 341
2) only recorded biofilm burden recovered from washed tissue pieces. However, there is 342 evidence in the literature that S. aureus may preferentially bind to mucus plugs in the airways 343 of the CF lung, rather than associating with the tissue surface. This could explain why, despite 344 presumably being adapted to the lung environment, CFU loads associated specifically with 345 the bronchiolar tissue showed such a marked drop by day 7. When bacteria were also 346 recovered from the surrounding ASM and enumerated, the total CFU count from the sample 347 (tissue plus surrounding ASM) was higher than the CFU count for tissue only, for all strains 348 except FQ210 (Fig 4a) . In fact, by day 7, a greater proportion of the total bacterial population 349 is consistently found in the surrounding ASM than in tissue-associated biofilm (Fig 4b) 
379
Linear models on log-log transformed data showed a significant correlation between growth associated with tissue Small colonies (<50% diameter of usual S. aureus colonies) were observed on MSA plates after 390 incubation for at least 48 h in 5% CO2 at 37 °C for samples taken 7 days post inoculation. 391 Exemplar colonies were photographed (Fig S1) . These potential SCVs were tested for 392 identification and confirmation against WT colonies ( Tolerance to rifampicin was observed for four selected clinical isolates and USA300 when 413 infected tissues were incubated with rifampicin at >500-fold MIC (2 µg mL -1 ) for 24 h at 37 °C 414 (Fig 5) . Uninfected control tissues showed no growth on MSA agar plates. All selected S. 415 aureus strains showed a sensitive resistance profile to rifampicin, with an MIC of 0.0039 µg 416 ml -1 (Table S1 ). The data were analyzed by ANOVA to test for differences between strains, 417 lungs and rifampicin treatment. The analysis showed an overall decrease in bacterial load 418 across strains following rifampicin exposure (F1,49 = 468, p < 0.001), and this was not strain 419 dependent (strain*treatment interaction F1,49 = 1.81, p = 0.141). Consistent with biofilm 420 growth conferring antibiotic tolerance, only 2-3 log killing was found on exposure to >500-421 fold MIC. The use of in vivo animal models is limited by ethical concerns, cost and host immune 500 response (35). In an effort to reduce and replace the use of animal models, in vitro models 501 have been developed to represent the molecular mechanisms and phenotypic characteristics 502 of disease. Tissue culture monolayers, using cell lines and primary cell culture, have been used 503 extensively to study the interaction of the host epithelial layer and pathogens, most notably 504 P. aeruginosa (61-66). However, these models are often over simplistic in nature and lack 505 properties relating to the host tissue such as mucus hypersecretion, cell polarity, differential 506 cell types, and tissue structure and integrity (67). Biofilms in these models were grown on 507 abiotic surfaces and such in vitro biofilms have been shown to differ from in vivo biofilm in a 508 number of significant ways (68). More specifically for the incidence of S. aureus in CF, it is alsoabundantly clear that both mouse and in vitro models fail to capture key features of pathology 510 observed from human clinical data. Our EVPL model could thus fill an important gap in our 511 toolkit for answering crucial questions about the microbiology and clinical impact of S. aureus 512 in CF. To this end, we present a critique of the model as it currently stands. 513 514 Variability in S. aureus bacterial load in the model is considerable, and there are a number of 515 possible explanations. For example, there may be differences in starting inocula. Lungs were 516 inoculated from single colonies, and not a standardized broth culture, as preliminary work 517 with P. aeruginosa in the model showed no significant variation in the number of cells 518 inoculated from single colonies, or the cell numbers recorded at 48 h (34). However, given 519 the differences in the way that the two bacteria grow in the model, starting inoculum may be 520 a more significant determinant of the growth and survival of S. aureus in the model thus 521 warranting further study. Standardized cell numbers would be important if, for example, the 522 model were to be developed to measure the impact of antimicrobial agents on viable 523 bacterial burden. It is worth noting that if the tissue-associated subpopulation of S. aureus 524 grows as a biofilm and not within the tissue (Fig 3) , then surface area of tissue sections may 525 have a significant impact on the bioburden in each tissue sample and further standardisation 526 of tissue sample size and shape may improve consistency. 527 528 Conversely, in the lung airway there is unlikely to be a large burden of colonising bacteria (69), 529 but rather a few seeding cells transferred from the upper airway. In this respect, inoculating 530 from a single colony may actually more closely reflect the clinical situation, and was therefore 531 regarded as sufficient to study the initial establishment, growth and maintenance of S. aureus 532 within the scope of this study. More data on the variability in S. aureus aggregate sizebetween foci of infection within the lungs, and between patients, would be needed to answer 534 this question. In a study by Hirschhausen et al. (55) , adaptive changes differed in patients 535 infected with the same S. aureus clonal lineage, indicating that individual host factors had an 536 impact on adaption. This is reminiscent of our results, which show significant variability 537 between lungs taken from different pigs (Fig 2) . 538
539
In our initial growth studies (Figures 1 and 2 ) the decline in CFU count between day 2 and 7 540 was consistent, suggesting that despite variation between strains and lungs, growth patterns 541 for the same strain were reproducible. The reduction in cell count was also not due to the 542 model being unable to support S. aureus growth, as S. aureus CFU were observed at 7 days 543 and this was confirmed histologically (Fig 3) . Differences in the growth and localisation of a 544 pair of isolates taken from the same patient during stable infection and acute exacerbation 545 also warrant further exploration with a larger collection of isolates (Fig 3) . 546
547
Further empirical work, conducted with close attention to the available clinical data, is 548 required to fully assess the strengths and limitations of EVPL as a model for S. aureus CF 549 infection. However, the data we present show striking consistencies with clinical observations 550 which are not matched by mouse models, and back up the results of the only cell line study 551 which mimicked CF conditions by inducing mucus hypersecretion. We thus conclude that 552 EVPL plus ASM could be a valuable addition to the suite of infection and biofilm models 553 available to microbiologists. 
